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ABSTRACT
The in-vivo activity of imipenem against VIM-1-
producing Klebsiella pneumoniae (VPKP) was as-
sessed in a thigh infection model in neutropenic
mice. Animals were infected with three VPKP
isolates (imipenem MICs 2, 4 and 32 mg ⁄L,
respectively) and a susceptible clinical isolate
(MIC 0.125 mg ⁄L) that did not produce any b-
lactamase with broad-spectrum activity. Bacterial
density at the site of infection was determined
after imipenem treatment (30 and 60 mg ⁄ kg every
2 h for 24 h). The log10 reduction in CFU ⁄ thigh
was greatest for the wild-type isolate, intermedi-
ate for the two imipenem-susceptible VPKP iso-
lates, and lowest for the imipenem-resistant
VPKP isolate. Whilst in-vivo imipenem activity
appeared reduced against in-vitro susceptible
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VIM-1 producers compared with a VIM-1-nega-
tive control, an increased drug dosage could
moderate this reduction.
Keywords Animal model, imipenem, Klebsiella pneu-
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VIM-1
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VIM-1 metallo-b-lactamase-producing Klebsiella
pneumoniae (VPKP) strains are endemic in Greek
hospitals [1,2]. The b-lactam resistance patterns of
these isolates generally encompass all drugs
hydrolysed by VIM-1, i.e., all b-lactams except
aztreonam, but precise carbapenem MICs may
vary widely [3,4]. However, the correlation
between in-vitro susceptibility to carbapenems
and in-vivo activity of these agents against VPKP
has not been investigated actively to date. The
present study used a murine thigh infection
model to examine the in-vivo activity of imipe-
nem against VPKP isolates exhibiting varying
degrees of susceptibility to imipenem.
Three VPKP isolates (two with decreased
imipenem susceptibility, Kp-Ia and Kp-Ib, and
one resistant to imipenem, Kp-R) derived from
bacteraemic patients were used. A b-lactam-
susceptible K. pneumoniae blood isolate (Kp-S)
was used as a control. Typing by pulsed-ﬁeld gel
electrophoresis and characterisation of b-lacta-
mase content were performed as described pre-
viously [1]. MICs of selected b-lactam antibiotics
were determined using a microdilution tech-
nique with an inoculum of 6 log10 CFU ⁄mL.
Susceptibility to imipenem was also assessed
using a bacterial inoculum of 8 log10 CFU ⁄mL.
Minimum bactericidal concentrations of imipe-
nem at a cell density of 6 log10 CFU ⁄mL were
also determined.
Infection was induced in the thighs of neu-
tropenic female ICR mice weighing 28–32 g (Har-
lan Sprague Dawley, Indianopolis, IN, USA) by
injection of 0.1 mL of bacterial suspension
(7 log10 CFU ⁄mL) derived from log-phase cul-
tures grown in tryptic soy broth [5]. The animals
were rendered neutropenic (<100 neutro-
phils ⁄mm3) by intraperitoneal injection of 150
and 100 mg ⁄ kg of cyclophosphamide at day 4
and day 1, respectively, before the initiation of
infection. Treatment with imipenem was started
2 h after inoculation and lasted for 24 h. Two
dosing schemes were used: (A) 30 mg ⁄ kg and (B)
60 mg ⁄ kg, given every 2 h by interperitoneal
injection (total doses of 360 and 720 mg ⁄ kg,
respectively). Blood samples were taken 10, 20,
30, 60 and 120 min after injection of a single dose
of antibiotic (four infected animals for each time-
point). Plasma levels of imipenem were
determined by a microbiological assay using
Escherichia coli ATCC 25922 [6]. The number of
viable organisms per thigh was counted 0, 6 and
24 h after initiation of treatment, using four
animals for each time-point. Statistical analysis
was performed using the t-test. All animal proce-
dures were approved by the Veterinary Section of
the Greek Republic and conformed to European
Union guidelines.
Previous analysis of b-lactamase content
indicated that VIM-1 was the only enzyme with
broad-spectrum activity produced by Kp-Ia, Kp-Ib
and Kp-R. Isolate Kp-S only expressed the species-
speciﬁc penicillinase. The pulsed-ﬁeld gel electro-
phoresis patterns of the three VIM-1-producing
isolates were highly similar and corresponded to
the pulsed-ﬁeld gel electrophoresis type that is
currently prevalent among VPKP strains in Greek
hospitals (data not shown). b-Lactam resistance
patterns were consistent with the b-lactamase
content (Table 1). With an inoculum of 6 log10
CFU ⁄mL, imipenem MICs were 2, 4 and 32 mg ⁄L
for Kp-Ia, Kp-Ib and Kp-R, respectively. The
minimum bactericidal concentration values were
higher by one doubling dilution. Increasing the
inoculum by two orders of magnitude resulted
in a signiﬁcant increase in the apparent levels
of resistance to imipenem (MICs ‡256 mg ⁄L for
Table 1. In-vitro susceptibility of Klebsiella pneumoniae
isolates to selected b-lactam antibiotics and the in-vivo
efﬁcacy of imipenem
Isolate
MIC (mg/L) of antibiotics
Decrease in CFU/thigh
(log10)
a
Caz Atm Imi Mer Scheme A Scheme B
Kp-S 2 0.25 0.125 0.125 4.75 ± 0.2 4.85 ± 0.2
Kp-Ia >64 0.5 2 0.5 2.12 ± 0.36 3.74 ± 0.08
Kp-Ib >64 0.5 4 0.5 2.2 ± 0.31 2.58 ± 0.25
Kp-R >64 0.25 32 8 1.24 ± 0.26 1.27 ± 0.16
Caz, ceftazidime; Atm, aztreonam; Imi, imipenem; Mer, meropenem.
aMean decrease ± SD after completion of treatment (24 h) with imipenem.
Scheme A, 30 mg ⁄ kg every 2 h for 24 h; scheme B, 60 mg ⁄ kg every 2 h for 24 h.
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all three VIM-1 producers). However, the ino-
culum effect was less pronounced with Kp-S
(imipenem MICs of 0.125 and 1 mg ⁄L with 6 and
8 log10 CFU ⁄mL, respectively).
The mean peak imipenem concentration in
plasma with dosing scheme A was 23.2 mg ⁄L
(coefﬁcient of variation 10%), while that achieved
with scheme B was 48.6 mg ⁄L (coefﬁcient of
variation 10%). Peaks were observed 20 min after
intraperitoneal injection, followed by fast elimin-
ation with a half-life of 8 min. These values were
in agreement with the kinetics of bolus dosing of
imipenem in mice [7,8]. The calculated%T > MIC
values were 36.8 and 33.3 for Kp-Ia and Kp-Ib,
respectively, with scheme A, and 45.8 and 39.2,
respectively, with scheme B. Only with the latter
scheme was a %T > MIC of 18.3 achieved for
Kp-R. The %T > MIC values were 63.2 (sch-
eme A) and 71.7 (scheme B) for the control isolate
Kp-S.
The number of bacterial cells recovered from
the thighs of the infected animals before treatment
were comparable for all isolates. Fig. 1 summa-
rises the results obtained (CFU ⁄ thigh) for differ-
ent bacterial isolates at various time-points. Both
dosing schemes resulted in a substantial differ-
ence in the viable counts of Kp-S after 24 h
compared with untreated animals. A greater
effect was observed with dosing scheme B against
Kp-Ia and Kp-Ib, but the activity of both dosing
schemes against these two ‘imipenem-susceptible’
VPKP isolates was signiﬁcantly lower than for
Kp-S (p <0.001) (Table 1; Fig. 1).
The VIM-1 producers used in this study repre-
sent the main VPKP clone that has spread
throughout Greece. Most VPKP isolates appear
to be susceptible to imipenem, with MICs of 2–
4 mg ⁄L, similar to those for Kp-Ia and Kp-Ib.
Taking these MICs at face value, carbapenems are
often used for the treatment of the corresponding
infections. In the thigh infection model with
neutropenic mice, imipenem was less effective
against all three VPKP isolates than against a fully
susceptible non-VIM-1-producing strain. Never-
theless, a correlation between in-vitro susceptibil-
ity and in-vivo activity of imipenem was obvious,
in that the bactericidal effect was greatest against
the susceptible non-VIM-producing strain, inter-
mediate against the ‘susceptible’ VPKP strains,
and low against the resistant VPKP strain.
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Fig. 1. In-vivo killing kinetics of a
non-VIM-producing Klebsiella pneu-
moniae strain (Kp-S), and VIM-1-
producing K. pneumoniae strains
(Kp-Ia, Kp-Ib and Kp-R) in the
thighs of neutropenic mice treated
with imipenem 30 mg ⁄ kg (sche-
me A) or 60 mg ⁄ kg (scheme B)
every 2 h. Bacterial growth in un-
treated animals is also shown. 0 h
represents the time of initiation of
treatment.
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Obtaining drug plasma levels above theMIC for
a sufﬁcient period of time is critical for b-lactams to
effect optimal activity. For carbapenems, a target
exposure of 25–40% T > MIC is considered sufﬁ-
cient to achieve signiﬁcant antibacterial activity
[9,10]. Both of the treatment regimens used in the
present study maintained drug plasma levels
above the MIC for >30% of the time for all three
imipenem-susceptible isolates. By meeting this
requirement, imipenem produced an antibacterial
effect on the susceptible control isolate that is
maximal in thismodel [7]. Despite these favourable
pharmacokinetic parameters, imipenem had infer-
ior activity against the VPKP isolates. The antibac-
terial effect of the drug on the two susceptible
VPKP isolates was signiﬁcantly augmented by
doubling the dosage, as has also been reported for
aztreonam in an experimental rat model of
pneumonia caused by VIM-1-producing Pseudo-
monas aeruginosa [11]. Nevertheless, imipenem
activity remained lower than that obtained
against the susceptible control. A possible explan-
ation for the low-to-moderate activity of imipenem
against the susceptible VPKP isolates is the opera-
tion of an in-vivo inoculum effect, similar to that
observed in vitro. While the present data cannot
provide ﬁrm conclusions regarding the treatment
of infections caused by VPKP strains with imipe-
nem MICs in the susceptible range, they clearly
suggest that the administration of imipenem at
higher doses may prove to be of some beneﬁt.
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ABSTRACT
Risk-factors for bacteraemia were determined in a
case-control study of patients with Escherichia coli
urinary tract infection. Cases were deﬁned as
patients with E. coli urinary source bacteraemia,
and controls were chosen from among patients
with E. coli urinary tract infection without bacter-
aemia. Patient characteristics were collected
prospectively and the bacterial traits were deter-
mined. The phylogenetic background and viru-
lence factors of E. coli isolates did not differ
between cases and controls. In multivariate
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